Genmab A/S (NASDAQ:GMAB) Announces Quarterly Earnings Results

Genmab A/S (NASDAQ:GMAB) issued its quarterly earnings data on Wednesday. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29, Zacks reports. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. Genmab A/S updated its FY 2025 guidance to EPS.

Genmab A/S Price Performance

Shares of GMAB traded up $0.17 on Friday, reaching $21.09. 166,315 shares of the stock traded hands, compared to its average volume of 1,503,776. The firm has a market cap of $13.95 billion, a price-to-earnings ratio of 20.48, a P/E/G ratio of 0.54 and a beta of 0.96. Genmab A/S has a 12 month low of $18.64 and a 12 month high of $31.88. The stock’s 50-day moving average price is $20.66 and its 200-day moving average price is $23.20.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GMAB. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Finally, Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.